Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Keros Therapeutics Inc shares valued at $84,975,125 were sold by Pontifax Management 4 G.P. (20 on Oct 15 ’25. At $17.75 per share, Pontifax Management 4 G.P. (20 sold 4,787,331 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, ADAR1 Capital Management, LLC sold 5,389,264 shares, netting a total of over 95,659,436 in proceeds. Following the sale of shares at $17.75 each, the insider now holds 0 shares.
Before that, Rovaldi Christopher had added 85,306 shares to its account. In a trade valued at $1,340,157, the Affiliate bought Keros Therapeutics Inc shares for $15.71 each.
As published in their initiating research note from Wells Fargo on October 20, 2025, Keros Therapeutics Inc [KROS] has been an Overweight and the price target has been revised to $26. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early June. As of January 21, 2025, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for KROS. Earlier on January 17, 2025, Wedbush downgraded its rating. Their new recommendation was “a Neutral” for KROS stock which previously was a “an Outperform”.
Analyzing KROS Stock Performance
On last trading session, Keros Therapeutics Inc [NASDAQ: KROS] rose 0.44% to $20.36. The stock’s lowest price that day was $20.09, but it reached a high of $20.49 in the same session. During the last five days, there has been a drop of approximately -4.77%. Over the course of the year, Keros Therapeutics Inc shares have jumped approximately 24.00%. Shares of the company reached a 52-week high of $22.55 on 12/08/25 and a 52-week low of $9.12 on 04/09/25.
Support And Resistance Levels for Keros Therapeutics Inc (KROS)
According to the 24-hour chart, there is a support level at 20.08, which, if violated, would cause prices to drop to 19.79. In the upper region, resistance lies at 20.57. The next price resistance is at 20.77. RSI (Relative Strength Index) is 54.26 on the 14-day chart, showing neutral technical sentiment.
Is Keros Therapeutics Inc subject to short interest?
Stocks of Keros Therapeutics Inc saw a sharp steep in short interest on 2025-12-15 dropping by -4.09 million shares to 2.69 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 6.78 million shares. A decline of -151.87% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.43 of the overall float, the days-to-cover ratio (short ratio) decline to 2.43.
Which companies own the most shares of Keros Therapeutics Inc (KROS)?
In terms of Keros Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 105 in the next 12 months, up nearly 418.01% from the previous closing price of $20.27. Analysts anticipate Keros Therapeutics Inc stock to reach 107 by 2026, with the lowest price target being 96. In spite of this, 3 analysts ranked Keros Therapeutics Inc stock as Buy at the end of 2026. On December 16, 2024, Oppenheimer assigned a price target of “an Outperform” to the stock and reiterated coverage with a $63.
